Veronese N, Stubbs B, Solmi M, Ajnakina O, Carvalho AF, Maggi S
Javeri HA, Arora R, Correa AM, Dixon DR, Komaki R, Hofstetter WL, Rice DC, Walsh GL, Vaporciyan AA, Swisher SG , Lee JH, Bhutani M, Ross WA, Liao Z, Maru DM, Dekovich AA, Ajani JA
Key Takeaways Gastrointestinal events are the most common adverse effects: Nausea, diarrhea, and vomiting were reported in 4067% of participants at higher doses in published Phase 2 trial data Adverse events are dose-dependent: Higher retatrutide doses consistently produced higher rates of GI events across all published trials Most adverse events were mild to moderate: The Phase 2 trial reported the majority of events as Grade 1-2 in severity Discontinuation rates ranged from 610%: Published data shows dropout rates due to adverse events were comparable to other GLP-1 class compounds Retatrutide is not FDA-approved: All safety data comes from investigational clinical trials it remains a research compound What Clinical Trials Tell Us About Retatrutide Adverse Events Retatrutide (LY3437943) is an investigational triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously
To maximize uptake into muscle cells, it is best to take your L-carnitine supplement with a carbohydrate-rich meal before workouts
It's also widely available in fortified foods such as breakfast cereals and milks, both soy and cow
Many benefits, no issues." Believer Phil D
